Enhanced plasma miR‑142‑5p promotes the progression of intrahepatic cholangiocarcinoma via targeting PTEN

Wei,Guifen; Yuan,Yiting; He,Xinzhong; Jin,Liming; Jin,Di

doi:10.3892/etm.2019.7438

Enhanced plasma miR‑142‑5p promotes the progression of intrahepatic cholangiocarcinoma via targeting PTEN

Authors:
- Guifen Wei
- Yiting Yuan
- Xinzhong He
- Liming Jin
- Di Jin
View Affiliations

Affiliations: Department of Hepatobiliary and Pancreatic Surgery, The First People's Hospital of Tongxiang, Wutong, Tongxiang, Zhejiang 314500, P.R. China
Published online on: March 26, 2019 https://doi.org/10.3892/etm.2019.7438
Pages: 4190-4196

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the expression and specific role of microRNA (miR)‑142‑5p in the progression of intrahepatic cholangiocarcinoma (ICC). Reverse transcription‑quantitative polymerase chain reaction was performed to evaluate miR‑142‑5p expression in patients with ICC and healthy control subjects. The results revealed that plasma miR‑142‑5p was significantly increased in patients with ICC compared with the control group. Furthermore, miR‑142‑5p was also increased in ICC tissues compared with adjacent non‑neoplastic tissues. Compared with patients with Ta‑T1 stage ICC, miR‑142‑5p was significantly elevated in patients with ICC ≥T2 stage. Patients with ICC at G3 stage had much higher plasma miR‑142‑5p levels compared with those at G1/2 stage. Receiver operating characteristic analysis indicated that miR‑142‑5p could be used as a biomarker to differentiate patients with ICC from healthy controls. Kaplan‑Meier analysis demonstrated that plasma miR‑142‑5p was negatively correlated with survival in patients with ICC. A dual luciferase reporter assay indicated that miR‑142‑5p significantly suppressed the relative luciferase activity of pmirGLO‑PTEN‑3' untranslated region compared with the control group. In summary, the results of the present study provide novel data indicating that plasma miR‑142‑5p is significantly upregulated in patients with ICC. miR‑142‑5p may therefore have potential as a biomarker for screening patients with ICC from healthy controls.

View Figures

View References

1	Hu J, Chen FY, Zhou KQ, Zhou C, Cao Y, Sun HC, Fan J, Zhou J and Wang Z: Intrahepatic cholangiocarcinoma patients without indications of lymph node metastasis not benefit from lymph node dissection. Oncotarget. 8:113817–113827. 2017. View Article : Google Scholar : PubMed/NCBI
2	Ahn DH and Bekaii-Saab T: Biliary cancer: Intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: Classification and therapeutic implications. J Gastrointest Oncol. 8:293–301. 2017. View Article : Google Scholar : PubMed/NCBI
3	Bagante F, Spolverato G, Weiss M, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, et al: Impact of morphological status on long-term outcome among patients undergoing liver surgery for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 24:2491–2501. 2017. View Article : Google Scholar : PubMed/NCBI
4	Bhalla A, Mann SA, Chen S, Cummings OW and Lin J: Histopathological evidence of neoplastic progression of von meyenburg complex to intrahepatic cholangiocarcinoma. Hum Pathol. 67:217–224. 2017. View Article : Google Scholar : PubMed/NCBI
5	Chang ME, Lei HJ, Chen MH, Yeh YC, Li CP, Hung YP, Hsia CY, Liu CA, Chau GY and Chao Y: Evaluation of prognostic factors and implication of lymph node dissection in intrahepatic cholangiocarcinoma: 10-year experience at a tertiary referral center. J Chin Med Assoc. 80:140–146. 2017. View Article : Google Scholar : PubMed/NCBI
6	Chen Y, Liu D, Liu P, Chen Y, Yu H and Zhang Q: Identification of biomarkers of intrahepatic cholangiocarcinoma via integrated analysis of mRNA and miRNA microarray data. Mol Med Rep. 15:1051–1056. 2017. View Article : Google Scholar : PubMed/NCBI
7	Zhang RX, Zheng Z, Li K, Wu XH and Zhu L: Both plasma and tumor tissue miR-146a high expression correlates with prolonged overall survival of surgical patients with intrahepatic cholangiocarcinoma. Medicine (Baltimore). 96:e82672017. View Article : Google Scholar : PubMed/NCBI
8	Zhang S, Xiao J, Chai Y, Du YY, Liu Z, Huang K, Zhou X and Zhou W: LncRNA-CCAT1 promotes migration, invasion, and EMT in intrahepatic cholangiocarcinoma through suppressing miR-152. Dig Dis Sci. 62:3050–3058. 2017. View Article : Google Scholar : PubMed/NCBI
9	Zu C, Liu S, Cao W, Liu Z, Qiang H, Li Y, Cheng C, Ji L and Li J and Li J: MiR-590-3p suppresses epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma by inhibiting SIP1 expression. Oncotarget. 8:34698–34708. 2017. View Article : Google Scholar : PubMed/NCBI
10	Wang Z, Liu Z, Fang X and Yang H: MiR-142-5p suppresses tumorigenesis by targeting PIK3CA in non-small cell lung cancer. Cell Physiol Biochem. 43:2505–2515. 2017. View Article : Google Scholar : PubMed/NCBI
11	Islam F, Gopalan V, Vider J, Lu CT and Lam AK: MiR-142-5p act as an oncogenic microRNA in colorectal cancer: Clinicopathological and functional insights. Exp Mol Pathol. 104:98–107. 2018. View Article : Google Scholar : PubMed/NCBI
12	Zhang X, Yan Z, Zhang J, Gong L, Li W, Cui J, Liu Y, Gao Z, Li J, Shen L and Lu Y: Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Ann Oncol. 22:2257–2266. 2011. View Article : Google Scholar : PubMed/NCBI
13	Wittekind C: Pitfalls in the classification of liver tumors. Pathologe. 27:289–293. 2006.(In German). View Article : Google Scholar : PubMed/NCBI
14	Edge SB and Compton CC: The american joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Bartella I and Dufour JF: Clinical diagnosis and staging of intrahepatic cholangiocarcinoma. J Gastrointestin Liver Dis. 24:481–489. 2015.PubMed/NCBI
17	Rahnemai-Azar AA, Weisbrod A, Dillhoff M, Schmidt C and Pawlik TM: Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis. Surg Oncol. 26:125–137. 2017. View Article : Google Scholar : PubMed/NCBI
18	Pawlik TM: Intrahepatic cholangiocarcinoma: From diagnosis to treatment. Hepatobiliary Surg Nutr. 6:12017. View Article : Google Scholar : PubMed/NCBI
19	Wang S, Yin J, Li T, Yuan L, Wang D, He J, Du X and Lu J: Upregulated circulating miR-150 is associated with the risk of intrahepatic cholangiocarcinoma. Oncol Rep. 33:819–825. 2015. View Article : Google Scholar : PubMed/NCBI
20	Correa-Gallego C, Maddalo D, Doussot A, Kemeny N, Kingham TP, Allen PJ, D'Angelica MI, DeMatteo RP, Betel D, Klimstra D, et al: Circulating plasma levels of MicroRNA-21 and MicroRNA-221 are potential diagnostic markers for primary intrahepatic cholangiocarcinoma. PLoS One. 11:e01636992016. View Article : Google Scholar : PubMed/NCBI
21	Cheng Q, Feng F, Zhu L, Zheng Y, Luo X, Liu C, Yi B and Jiang X: Circulating miR-106a is a novel prognostic and lymph node metastasis indicator for cholangiocarcinoma. Sci Rep. 5:161032015. View Article : Google Scholar : PubMed/NCBI
22	Yuan R, Wang G, Xu Z, Zhao H, Chen H, Han Y, Wang B, Zhou J, Hu H, Guo Z, et al: Up-regulated circulating miR-106a by DNA methylation promised a potential diagnostic and prognostic marker for gastric cancer. Anticancer Agents Med Chem. 16:1093–1100. 2016. View Article : Google Scholar : PubMed/NCBI
23	Zhou GY, Pan CW, Jin LX, Zheng JJ and Yi YX: Neoalbaconol inhibits cell growth of human cholangiocarcinoma cells by up-regulating PTEN. Am J Transl Res. 8:496–505. 2016.PubMed/NCBI
24	Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, Mizuno K, Hasegawa G, Kishimoto H, Iizuka M, et al: Hepatocyte-specific pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest. 113:1774–1783. 2004. View Article : Google Scholar : PubMed/NCBI
25	Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, Creasap N, Thompson JC, Caserta E, Wang H, Chong JL, et al: Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature. 461:1084–1091. 2009. View Article : Google Scholar : PubMed/NCBI
26	Xu X, Kobayashi S, Qiao W, Li C, Xiao C, Radaeva S, Stiles B, Wang RH, Ohara N, Yoshino T, et al: Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and pten in mice. J Clin Invest. 116:1843–1852. 2006. View Article : Google Scholar : PubMed/NCBI
27	Marsh V, Davies EJ, Williams GT and Clarke AR: PTEN loss and KRAS activation cooperate in murine biliary tract malignancies. J Pathol. 230:165–173. 2013. View Article : Google Scholar : PubMed/NCBI
28	Chung JY, Hong SM, Choi BY, Cho H, Yu E and Hewitt SM: The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res. 15:660–667. 2009. View Article : Google Scholar : PubMed/NCBI
29	Lee YR, Chen M and Pandolfi PP: The functions and regulation of the PTEN tumour suppressor: New modes and prospects. Nat Rev Mol Cell Biol. 19:547–562. 2018. View Article : Google Scholar : PubMed/NCBI
30	Song MS, Salmena L and Pandolfi PP: The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 13:283–296. 2012. View Article : Google Scholar : PubMed/NCBI
31	Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, et al: Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 167:731–740. 2018. View Article : Google Scholar : PubMed/NCBI
32	Malaney P, Palumbo E, Semidey-Hurtado J, Hardee J, Stanford K, Kathiriya JJ, Patel D, Tian Z, Allen-Gipson D and Davé V: PTEN Physically interacts with and regulates E2F1-mediated transcription in lung cancer. Cell Cycle. 17:947–962. 2018. View Article : Google Scholar : PubMed/NCBI
33	Bian X, Gao J, Luo F, Rui C, Zheng T, Wang D, Wang Y, Roberts TM, Liu P, Zhao JJ and Cheng H: PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene. 37:341–351. 2018. View Article : Google Scholar : PubMed/NCBI
34	Ikenoue T, Terakado Y, Nakagawa H, Hikiba Y, Fujii T, Matsubara D, Noguchi R, Zhu C, Yamamoto K, Kudo Y, et al: Corrigendum: A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. Sci Rep. 7:395672017. View Article : Google Scholar : PubMed/NCBI
35	Ikenoue T, Terakado Y, Nakagawa H, Hikiba Y, Fujii T, Matsubara D, Noguchi R, Zhu C, Yamamoto K, Kudo Y, et al: A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. Sci Rep. 6:238992016. View Article : Google Scholar : PubMed/NCBI